Professor Gunnar Birgegard - Anagrelide and Myeloproliferative Disorders

Monday 16th October

Professor Birgegard presented: "Platelet reduction therapy in ET - present & future" at the Royal Tasmanian Yacht Club, Marieville Esplanade, Sandy Bay, Tasmania.The presentation was based on his review:

"Anagrelide Treatment in Myeloproliferative Disorders"
in Seminars in Thrombosis and Hemostasis, Vol 32, number 3, 2006

 

Professor Gunnar Birgegard is Professor of Haematology at Uppsala University, Uppsala, Sweden. His early research interests focused on iron metabolism and inflammation as well as erythropoietin pathophysiology, especially in Polycythaemia Vera. He is Chairman of the Nordic Study Group for Myeloproliferative disorders and is currently involved with studies on platelet reduction therapy with anagrelide and interferon. He is also a member of the Steering Committee for Leukemia Network Work Package 9 on Myeloproliferative disorders.